STOCK TITAN
  1. Home
  2. Sec-filings
  3. PRLD
  4. [EFFECT] Prelude Therapeutics Inc SEC Filing

[EFFECT] Prelude Therapeutics Inc SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: December 16, 2025 4:00 P.M.
Form: S-3
CIK: 0001678660
Company Name: Prelude Therapeutics Inc
File Number: 333-292048

Source: View Original Filing on SEC EDGAR

Stock PRLD logo
Prelude Therapeutics Inc

NASDAQ:PRLD

PRLD Rankings

#4661 Ranked by Market Cap
N/A Ranked by Dividends

PRLD Latest News

Feb 3, 2026
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Dec 6, 2025
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
Nov 12, 2025
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 4, 2025
Prelude Therapeutics Announces Strategic Business Update
Nov 4, 2025
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

PRLD Latest SEC Filings

Feb 13, 2026
[SCHEDULE 13G/A] Prelude Therapeutics Inc Amended Passive Investment Disclosure
Feb 5, 2026
[Form 4] Prelude Therapeutics Inc Insider Trading Activity
Feb 5, 2026
[Form 4] Prelude Therapeutics Inc Insider Trading Activity
Feb 5, 2026
[Form 4] Prelude Therapeutics Inc Insider Trading Activity
Feb 5, 2026
[Form 4] Prelude Therapeutics Inc Insider Trading Activity

PRLD Stock Data

165.34M
34.14M
Biotechnology
Pharmaceutical Preparations
Link
United States
WILMINGTON